Bevacizumab-associated Bowel Perforation：a Case Report and Literature Review

Meng-meng ZHANG,Sen CHEN,Suo-di ZHAI

DOI: https://doi.org/10.3969/j.issn.1672-3384.2014.013

2014-01-01

Abstract:Objective:To investigate the incidence, clinical manifestations, mechanism, risk factors and management of bevacizumab-associated bowel perforations.Methods: A stage IV colon cancer patient with bevacizumab-associated bowel perforation 442 days after the initiation of chemotherapy and bevacizumab was reported. And relevant research literatures were reviewed.Results and Conclulion :The incidence of bevacizumab-associated bowel perforations is low. Abdominal pain, nausea and vomiting, and fever could be complained by the patients. Although the mechanism is unknown now, many risk factors would contribute to the occurrence of this kind of severe adverse events. The detection and management of these patients should be emphasized.